The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell
lung cancer (SCLC) and high-grade neuroendocrine carcinomas. Rovalpituzumab teserine (…

Human epidermal growth factor receptor 2 (HER2) gene amplification and/or protein
overexpression in tumors is a prerequisite for initiation of trastuzumab therapy. Although HER2 is a …

A critical benchmark in the development of antibody-based therapeutics is demonstration of
efficacy in preclinical mouse models of human disease, many of which rely on …

Background Pretargeting-based approaches are being investigated for radioimmunoimaging
and therapy applications to reduce the effective radiation burden to the patient. To date, …

pH (low) insertion peptides (pHLIP peptides) target acidic extracellular environments in vivo
due to pH-dependent cellular membrane insertion. Two variants (Var3 and Var7) and wild-…

Purpose: Advances in our understanding of the contribution of aberrant glycosylation to the
pro-oncogenic signaling and metastasis of tumor cells have reinvigorated the development …

Tumors are composed of cancer cells but also a larger number of diverse stromal cells in the
tumor microenvironment. Stromal cells provide essential supports to tumor pathophysiology …

Delta-like ligand 3 (DLL3) is a therapeutic target for the treatment of small cell lung cancer,
neuroendocrine prostate cancer, and isocitrate dehydrogenase mutant glioma. In the clinic, …

AIM: To determine if other molecules reported to modulate AMP-dependent protein kinase (AMPK)
activity would have effects resembling those of metformin and phenformin on colon …

Methods We have developed a nuclear and fluorescence labeling strategy for nanocrystalline
cellulose (CNC), an emerging biomaterial with versatile chemistry and facile preparation …